에 대한 최신 뉴스 Viatris (NASDAQ:VTRS) 주식

VIATRIS INC

Viatris

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Equities

Large Cap

News

Movers

Trading Ideas

$BTC

CART

DUOL

MSTR

NTAP

PLTR

PSTG

SMCI

TCOM

TSLA

VTRS

지난주에 가장 저조한 성과를 보인 12개의 대형주는 다음과 같다.

테슬라·팔란티어·스트레티지 등 지난주 급락한 대형주 12종목 (2월 24일~28일)

Germany,,Bad,Homburg,,January,28.,2025,,Sign,Or,Lettering,Of

WIIM

비아트리스(NASDAQ:VTRS)의 주식이 금요일 오후 4% 이상 하락했지만 최근의 지지선 위에서 거래되고 있었다. 이는 어제 주가가 15% 하락한 후 발생한 일이다. 주가가 하락한 이유는 이 회사의 실적이 시장 예상보다 저조하게 나타났기 때문이다. 

오늘의 주식: 비아트리스의 주식은 지지선에서 반등할 수 있을까?

Healthcare,,Opioid,Epidemic,And,Drug,Abuse,Concept,With,The,Map

Analyst Color

Biotech

Health Care

Analyst Ratings

General

ABBV

ELAN

GILD

IDXX

PRGO

REGN

TEVA

JP모건에 따르면 미국 대형 바이오제약주는 2년 연속 전체 시장 대비 저조한 실적을 기록했으며, 2025년에 대한 투자자들의 전망은 혼조세를 보이고 있다. 강력한 펀더멘털과 신약 파이프라인의 발전에도 불구하고 정치적 불확실성과 섹터 순환과 같은 요인으로 인해 S&amp;P 500 대비 바이오제약 섹터의 성과가 저조했다. 

일라이 릴리, 머크 등 대형 바이오제약사 2025년 전망: JP모건

Viatris Inc

Vital Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTLE#NYSE">VTLE</a>) has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Vital Energy, presenting an average target of $20.75, a high estimate of $27.00, and a low estimate of $15.00. A 24.87% drop is evident in the current average compared to the previous average price target of $27.62. 
<img src="https://www.benzinga.com/files/images/story/2025/1750104066_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Vital Energy by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hanwen Chang</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$21.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Paul Diamond</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$17.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Noah Hungness</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$27.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Hanwen Chang</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$24.00</td>
<td>$36.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Vital Energy. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Vital Energy compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Vital Energy's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Vital Energy's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/VTLE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Vital Energy analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Vital Energy</h2>
Vital Energy is an independent energy company. Its business is focused on the acquisition, exploration, and development of oil and natural gas properties in the Permian Basin of West Texas. The Company has identified one operating segment: exploration and production.
<h3>Financial Insights: Vital Energy</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining Vital Energy's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.19% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Energy sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -3.68%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -0.7%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Vital Energy's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.33%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a high debt-to-equity ratio of 0.9, Vital Energy faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VTLE

Deep Dive Into Vital Energy Stock: Analyst Perspectives (8 Ratings)

During the last three months, 15 analysts shared their evaluations of Cisco Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>), revealing diverse outlooks from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">7</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Cisco Systems, revealing an average target of $68.53, a high estimate of $75.00, and a low estimate of $60.00. Experiencing a 0.39% decline, the current average is now lower than the previous average price target of $68.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1750104058_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Cisco Systems by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Niknam</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$73.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Amit Daryanani</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$72.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>James Fish</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$64.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Atif Malik</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$71.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Meta Marshall</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$67.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Tim Long</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$66.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$73.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Mike Genovese</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$74.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Aaron Rakers</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Amit Daryanani</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$67.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Mike Genovese</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Buy</td>
<td>$63.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$70.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Atif Malik</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$68.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Meta Marshall</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>James Fish</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$72.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Cisco Systems. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Cisco Systems compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Cisco Systems's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Cisco Systems's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CSCO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Cisco Systems analyst ratings.</a>
<h2>All You Need to Know About Cisco Systems</h2>
Cisco Systems is the largest provider of networking equipment in the world and one of the largest software companies in the world. Its largest businesses are selling networking hardware and software (where it has leading market shares) and cybersecurity software such as firewalls. It also has collaboration products, like its Webex suite, and observability tools. It primarily outsources its manufacturing to third parties and has a large sales and marketing staff—25,000 strong across 90 countries. Overall, Cisco employs 80,000 people and sells its products globally.
<h3>Understanding the Numbers: Cisco Systems's Finances</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Positive Revenue Trend: Examining Cisco Systems's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.39% as of 30 April, 2025, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Cisco Systems's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 17.61% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Cisco Systems's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.45% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Cisco Systems's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.07%, the company showcases efficient use of assets and strong financial health.
Debt Management: Cisco Systems's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.64.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CSCO

Cisco Systems Stock: A Deep Dive Into Analyst Perspectives (15 Ratings)

In the last three months, 7 analysts have published ratings on Antero Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AR#NYSE">AR</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Antero Resources and provided 12-month price targets. The average target is $46.29, accompanied by a high estimate of $57.00 and a low estimate of $40.00. Marking an increase of 4.52%, the current average surpasses the previous average price target of $44.29. 
<img src="https://www.benzinga.com/files/images/story/2025/1750104043_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Antero Resources among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$40.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Kalei Akamine</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$47.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>John Freeman</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$57.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$49.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$43.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>David Deckelbaum</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$46.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$42.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Antero Resources. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Antero Resources compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Antero Resources's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Antero Resources's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Antero Resources analyst ratings.</a>
<h2>Delving into Antero Resources's Background</h2>
Antero Resources, based in Denver, engages in the exploration for and production of natural gas and natural gas liquids in the United States and Canada. At the end of 2024, the company reported proven reserves of 17.9 trillion cubic feet of natural gas equivalent. Production averaged approximately 3,424 million cubic feet of equivalent a day in 2024 at a ratio of 35% liquids and 65% natural gas.
<h3>Financial Milestones: Antero Resources's Journey</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Antero Resources's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 31.68% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Energy sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 14.93%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Antero Resources's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.92% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Antero Resources's ROA excels beyond industry benchmarks, reaching 1.6%. This signifies efficient management of assets and strong financial health.
Debt Management: Antero Resources's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.53.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 7 Analyst Projections For Antero Resources

Buybacks

FITB

Fifth Third Bancorp Announces 100M Share Repurchase Authorization

15 analysts have shared their evaluations of APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">9</td>
<td align="right">4</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for APA, presenting an average target of $20.73, a high estimate of $30.00, and a low estimate of $14.00. A 10.65% drop is evident in the current average compared to the previous average price target of $23.20. 
<img src="https://www.benzinga.com/files/images/story/2025/1750104036_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of APA among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>John Freeman</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$25.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Devin McDermott</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$21.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>William Janela</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$19.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Betty Jiang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$19.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$30.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Devin McDermott</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$20.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Paul Cheng</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$14.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Scott Hanold</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$24.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Devin McDermott</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$22.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$23.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to APA. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of APA compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of APA's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into APA's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/APA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on APA analyst ratings.</a>
<h2>About APA</h2>
APA Corp is an independent exploration and production company. It develops, and produces crude oil, natural gas, and natural gas liquids. The Company's business has oil and gas operations in three geographic areas: the United States (U.S.), Egypt, and offshore the U.K. in the North Sea (North Sea). APA also has active development, exploration, and appraisal operations ongoing in Suriname, as well as exploration interests in Uruguay, Alaska, and other international locations.
<h3>Financial Insights: APA</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: APA's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 35.11%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Energy sector.
Net Margin: APA's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 13.16% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): APA's ROE stands out, surpassing industry averages. With an impressive ROE of 6.48%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): APA's ROA excels beyond industry benchmarks, reaching 1.83%. This signifies efficient management of assets and strong financial health.
Debt Management: APA's debt-to-equity ratio surpasses industry norms, standing at 1.01. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>What Are Analyst Ratings?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing APA: Insights From 15 Financial Analysts

BlackRock's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) short percent of float has fallen 13.95% since its last report. The company recently reported that it has 1.69 million shares sold short, which is 1.11% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.79 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>BlackRock Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750104030_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for BlackRock has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing BlackRock's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, BlackRock's peer group average for short interest as a percentage of float is 3.80%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into BlackRock's Recent Short Interest

Throughout the last three months, 9 analysts have evaluated Allison Transmission (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALSN#NYSE">ALSN</a>), offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $97.11, along with a high estimate of $110.00 and a low estimate of $79.00. Observing a downward trend, the current average is 6.12% lower than the prior average price target of $103.44. 
<img src="https://www.benzinga.com/files/images/story/2025/1750104028_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Allison Transmission. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sherif El-Sabbahy</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$79.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Jerry Revich</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$90.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Angel Castillo</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$100.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Angel Castillo</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$94.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Luke Junk</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Tim Thein</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$98.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Kyle Menges</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$95.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Kyle Menges</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$108.00</td>
<td>$115.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Allison Transmission. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Allison Transmission compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Allison Transmission's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ALSN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Allison Transmission analyst ratings.</a>
<h2>Unveiling the Story Behind Allison Transmission</h2>
Allison Transmission is the largest manufacturer of fully automatic transmissions for commercial vehicles. The company's automatic transmissions allow customers to achieve better fuel and operator efficiency than less expensive manual and automated manual transmissions. Allison serves several end markets, including on- and off-highway equipment and military vehicles. Its on-highway business has about 60% global market share. The company's transmissions can be found in Class 4-8 trucks, buses, and a limited number of large passenger vehicles (heavy-duty pickup trucks and motor homes). Allison also produces electric hybrid propulsion systems and is developing e-powertrains.
<h3>Allison Transmission: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Challenges: Allison Transmission's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -2.92%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Allison Transmission's net margin is impressive, surpassing industry averages. With a net margin of 25.07%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Allison Transmission's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 11.58% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Allison Transmission's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.59% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Allison Transmission's debt-to-equity ratio stands notably higher than the industry average, reaching 1.44. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALSN

Demystifying Allison Transmission: Insights From 9 Analyst Reviews

S&amp;P Global's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) short percent of float has fallen 20.41% since its last report. The company recently reported that it has 2.38 million shares sold short, which is 0.78% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.11 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>S&amp;P Global Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750104025_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for S&amp;P Global has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing S&amp;P Global's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, S&amp;P Global's peer group average for short interest as a percentage of float is 5.95%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

SPGI

Is the Market Bullish or Bearish on S&P Global?

Vertiv Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) short percent of float has fallen 14.46% since its last report. The company recently reported that it has 10.65 million shares sold short, which is 2.84% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.04 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Vertiv Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750104019_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Vertiv Holdings has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Vertiv Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Vertiv Holdings's peer group average for short interest as a percentage of float is 13.94%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Vertiv Holdings's Recent Short Interest

In the preceding three months, 6 analysts have released ratings for Ovintiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OVV#NYSE">OVV</a>), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $50.0, a high estimate of $58.00, and a low estimate of $41.00. This current average represents a 1.57% decrease from the previous average price target of $50.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1750104020_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A clear picture of Ovintiv's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$41.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$58.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Betty Jiang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$53.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$46.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Devin McDermott</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$57.00</td>
<td>-</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$45.00</td>
<td>$44.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ovintiv. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ovintiv compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Ovintiv's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Ovintiv's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/OVV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ovintiv analyst ratings.</a>
<h2>All You Need to Know About Ovintiv</h2>
Ovintiv Inc is a North American oil and natural gas exploration and production company that is focused on developing its multi-basin portfolio of high-quality assets located in the United States and Canada. Its operations also include the marketing of oil, NGLs and natural gas. The company has two operating segments: USA Operations, and Canadian Operations. The USA Operations include the exploration for, development of, and production and marketing of oil, NGLs, natural gas and other related activities within the United States. The Canadian Operations include the exploration for, development of, and production and marketing of oil, NGLs, natural gas and other related activities within Canada.
<h3>Financial Insights: Ovintiv</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Ovintiv displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 1.06%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Energy sector.
Net Margin: Ovintiv's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -6.69%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -1.56%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Ovintiv's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.82%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Ovintiv's debt-to-equity ratio is below the industry average. With a ratio of 0.67, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Ovintiv's Future

In the current session, the stock is trading at $298.27, after a 2.09% spike. Over the past month, Autodesk Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) stock increased by 0.82%, and in the past year, by 22.18%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1750104018_0.png" alt="Past Year Chart" />

<h3>How Does Autodesk P/E Compare to Other Companies?</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 193.52 in the Software industry, Autodesk Inc. has a lower P/E ratio of 62.7. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1750104019_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

ADSK

Price Over Earnings Overview: Autodesk

Regencell Bioscience Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares are soaring Monday after the company&#8217;s 38-for-one forward stock <a href="https://regencellbioscience.com/regencell-bioscience-holdings-limited-announces-forward-stock-split/">split officially took effect</a>.
What To Know: The split, announced at the beginning of June and distributed on June 13, gave shareholders 37 additional shares for each one they already owned. The stock began trading on a split-adjusted basis on Monday. The company stated that the goal of the split was to improve liquidity and make its shares more accessible to investors.
Regencell is an early-stage bioscience company based in Hong Kong. The company focuses on developing traditional Chinese medicine treatments for neurological disorders, specifically ADHD and autism spectrum disorder.
The stock split doesn't alter the company's fundamentals or financial outlook. The sharp spike in the company&#8217;s share price likely reflects speculative interest following the split. Investors may be reacting to the lower price per share post-split, which can drive short-term volume and volatility.
<h3 class="wp-block-heading">How To Buy RGC Stock</h3>
By now you're likely curious about how to participate in the market for Regencell Bioscience &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
RGC Price Action: Regencell Bioscience shares were up 276.5% at $59.21 at the time of publication Monday, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45952716/stock-market-today-sp500-rises-iran-israel-nasdaq-near-record-highs">Wall Street Roars Back As Iran Signals De-Escalation: Nasdaq 100 Nears All-Time High </a></li>
</ul>
Image via Shutterstock.

Stock Split

What's Going On With Regencell Bioscience Stock Today?

<a href="https://www.bloomberg.com/news/articles/2025-06-16/starmer-trump-set-to-agree-to-implement-tariff-cutting-pact" title="https://www.bloomberg.com/news/articles/2025-06-16/starmer-trump-set-to-agree-to-implement-tariff-cutting-pact">https://www.bloomberg.com/news/articles/2025-06-16/starmer-trump-set-to-agree-to-implement-tariff-cutting-pact</a>

Macro Economic Events

Politics

Global

Economics

'Starmer, Trump Set to Agree to Implement Tariff-Cutting Pact' - Bloomberg News

Cantor Fitzgerald on Monday initiated coverage on three Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) treasury companies—DeFi Development Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFDV#NASDAQ">DFDV</a>), Upexi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPXI#NASDAQ">UPXI</a>), and SOL Strategies (CSE:<a class="ticker" href="https://www.benzinga.com/stock/HODL#CSE">HODL</a>), predicting significant share price growth as Solana's high-performance blockchain gains traction in digital finance. 
The research report assigns "Overweight" ratings with price targets of $45 for DFDV (74.9% upside), $16 for UPXI (59.8% upside), and C$4 for HODL.CN (65.3% upside), driven by Solana's technological edge and the companies' strategic capital-raising plans.
The report highlights Solana's ability to process 65,000 transactions per second with sub-$0.01 fees, positioning it to challenge Ethereum's dominance. 
See Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45958855/srm-entertainment-shares-are-up-by-more-than-500-whats-going-on">SRM Entertainment Shares Are Up By More Than 500%: What&#8217;s Going On?</a>
"Developer growth on SOL has far exceeded that on ETH recently, and we expect this to continue," the analysts states, underscoring Solana's potential to overtake Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), which has a market cap 259% larger than Solana's $86.3 billion.
DeFi Development Corp. is positioned as a leader, with a crypto-native management team and validator acquisitions. 
"DFDV has the second-largest SOL position, has a crypto-native management team, has acquired multiple validators, and has access to the U.S. and European capital markets," the report notes. 
The firm expects DFDV to raise "$250m in annual capital markets proceeds at an average premium of 250%," leveraging its U.S. listing to boost SOL-per-share.
Upexi, with the largest SOL holding at 679,677 tokens, benefits from NASDAQ liquidity but lacks validator operations. 
"Upexi currently has the largest SOL position, sitting at 679,677, all of which was amassed this year," the report states. 
It projects UPXI raising "$250m in annual capital markets proceeds at an average premium of 200%," though its non-crypto-native management and reliance on delegated staking may limit long-term SOL accretion.
Also Read: <a href="https://www.benzinga.com/crypto/25/06/45951049/justin-suns-tron-plans-us-public-listing-amid-deepening-ties-with-trump-family-and-crypto-political-shift">Justin Sun&#8217;s Tron Plans US Public Listing Amid Deepening Ties With Trump Family And Crypto-Political Shift</a>
SOL Strategies, trading on the Canadian Securities Exchange, is nearing a NASDAQ listing, a key catalyst. 
"HODL is close to the finish line for a potential U.S. listing, with a few ‘short items' being sorted," the analysts write, noting that this could "supercharge demand and liquidity" compared to its current $0.387 billion trailing twelve-month average daily volume.
The report emphasizes staking as a growth driver, with 66% of SOL staked yielding returns above the 4.518% inflation rate. 
"Combining staking with treasury operations should result in Solana treasury companies growing SOL/share faster than BTC treasury companies," the analysts assert, highlighting DFDV and HODL's validator operations as an advantage over UPXI.
Real-world adoption bolsters Solana's outlook, with initiatives like Robinhood's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) blockchain-based securities trading, Apollo's $82 million tokenized credit fund, and Kraken's 24/7 tokenized U.S. stock trading. 
These projects "highlight increasing user interactions due to the blockchain's high throughput and low fees," per the report.
However, risks loom, including regulatory uncertainty around SOL's classification and potential Solana ETF approvals. 
"If the SEC classifies SOL as a security, this will add significant reporting, disclosure, and compliance requirements," the analysts warn. 
A Bloomberg-estimated 70% chance of ETF approval could reduce demand for treasury companies, though their staking benefits maintain appeal.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45947687/stablecoins-set-to-be-internets-digital-cash-genius-act-may-position-us-as-global-hub-says-bernstein">Stablecoins Set To Be Internet&#8217;s Digital Cash, GENIUS Act May Position US As Global Hub, Says Bernstein</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ETH

$SOL

CSE:HODL

DFDV

HODL

HOOD

UPXI

Solana Treasury Firms Get Cantor Vote Of Confidence: 'We Expect Developer Growth To Continue'

iShares MSCI Israel Capped Investable Market Index Fund

ISRA

Reuters Citing Iranian State TV Saying Iran Launches Combined Drone And Missile Operations Targeting Tel Aviv And Haifa

BALL

Ball shares are trading higher after the company announced a $250 million accelerated share repurchase agreement.

Ball Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALL#NYSE">BALL</a>) announced today an agreement to repurchase approximately $250 million of its outstanding common stock in a privately negotiated, accelerated stock repurchase transaction with Crédit Agricole CIB, using cash on hand and available borrowings.
Subject to certain conditions, the transaction will commence today and will significantly reduce Ball's outstanding common stock. Final share counts will be determined based on the volume weighted average price over the agreement period and subject to customary market‑price adjustment terms at the conclusion of the accelerated stock repurchase transaction, which may require a settlement to be made by Ball, or to Ball, based generally on the volume weighted average trading price of the company's common stock over an agreed upon period of time.

Reported Earlier: Ball Corp Announces $250M Accelerated Stock Repurchase Agreement

EchoStar Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATS#NASDAQ">SATS</a>) shares are trading higher Monday following reports indicating President Donald Trump stepped in to mediate a high-stakes spectrum dispute between the company and the Federal Communications Commission (FCC).
What To Know: The stock movement came after it was revealed that Trump met with EchoStar President Charlie Ergen and FCC Chairman Brendan Carr in the Oval Office to push for a resolution regarding the company's threatened wireless spectrum licenses, according to <a href="https://www.bloomberg.com/news/articles/2025-06-13/trump-urged-ergen-carr-to-cut-a-deal-on-echostar-spectrum?embedded-checkout=true">Bloomberg.</a>
The FCC had launched an investigation in May into whether EchoStar was fulfilling its obligations to utilize valuable spectrum assets for wireless and satellite communications. Facing mounting pressure from regulators and financial strain, including missed bond payments and discussions of potential bankruptcy, Ergen sought direct talks with Carr. After initial attempts to reach him were unsuccessful, the two finally met Wednesday. Carr reportedly told Ergen that EchoStar risked losing its licenses unless it began selling portions of its underutilized spectrum.
 Trump, concerned about the broader implications of a major American company collapsing, called Carr into the Oval Office during the meeting and urged both parties to reach an agreement. 
While EchoStar has not yet made any public statements, the White House has also declined to comment on specifics. 
EchoStar Price Action: EchoStar shares were up 48.5% at $25.01 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45952716/stock-market-today-sp500-rises-iran-israel-nasdaq-near-record-highs">Wall Street Roars Back As Iran Signals De-Escalation: Nasdaq 100 Nears All-Time High</a></li>
</ul>
Image Via Shutterstock.

SATS

What's Going On With EchoStar Shares Today?

Christopher Perkins, President of CoinFund and a former Wall Street executive, believes the next chapter of crypto adoption hinges on clarity—<a href="http://www.benzinga.com/markets/cryptocurrency/25/02/44063764/cryptos-trump-era-honeymoon-fades-as-regulatory-reality-sets-in">regulatory, technological, and strategic. </a>
In an interview with Benzinga, Perkins discussed everything from AI-powered networks to staking yields, tokenized fund structures, and Washington's evolving stance on digital assets.
At the heart of Perkins&#8217; long-term thesis is a commitment to fundamentals over hype. 
When asked about the investability of AI-token and DePIN projects, he was blunt: "We don't like to invest on narrative. We like to invest on fundamentals." 
CoinFund has made numerous bets in the space. 
"It&#8217;s all about utility. It&#8217;s all about understanding the value that is derived from that utility," he said, pointing to examples like autonomous lawn robots powered by hyper-precise location data from DePIN networks.
Perkins is no stranger to regulatory entanglements. 
A former managing director at Citi during the Dodd-Frank era, he learned early on that "you can't win the game if you don't know the rules." 
Today, he sees the absence of a clear taxonomy, particularly around what constitutes a security versus a commodity, as the biggest hurdle to U.S. innovation. 
"What we're confronted with right now&#8230; is glitter clarity," he said, referring to the SEC's ambiguity under former chair Gary Gensler. 
Perkins remains optimistic about the new administration, describing the approach under President Donald Trump and current congressional leaders as "principled" and "coordinated."
Stablecoins, in his view, are on the verge of a breakout. 
With a Senate vote on stablecoin legislation expected soon, Perkins pointed to growing interest from the U.S. Treasury and traditional finance institutions. 
"Today, we're at $250 billion in stablecoin market cap. That could expand to $2 trillion, according to the Treasury." For DeFi, this capital influx could be transformative. 
"There's no yield today. Guess what? That's a depreciating asset unless you find yield&#8230; and those agents, those AIs that are now coming on the scene, are going to help optimize that."
On staking, Perkins sees parallels between proof-of-stake layer-1s and traditional finance benchmarks. 
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45957567/bitcoin-ethereum-lead-1-9-billion-digital-asset-inflows-amid-global-tensions-coinshares-finds">Bitcoin, Ethereum Lead $1.9 Billion Digital Asset Inflows Amid Global Tensions, CoinShares Finds</a>
"Every single layer-1&#8230; has a benchmark rate. That rate can unleash an entire array of fixed-income products." 
While most retail users focus on price action, institutions are eyeing yield curves and staking-derived returns as the next structured product opportunity.
Perkins is also enthusiastic about tokenization, calling it crypto's "secret power of capital formation." 
He noted that the meme coin market reached $40 billion last year, compared to just $30 billion for the entire venture capital market. 
"Anyone with an internet connection around the world can access these asset classes," he said. With minor regulatory assistance, tokenized fund structures could democratize exposure to previously inaccessible public markets.
Asked about the future of blockchain architecture, Perkins avoids binary arguments. "We're not monolithic versus modular maxis," he explained. 
While institutions tend to prefer modular ecosystems for control and customization, monolithic chains like Solana continue to deliver high-throughput applications that are difficult to ignore.
Perkins also addressed growing interest from retail giants in consumer-facing stablecoins. 
"Walmart and Amazon are talking about launching one. The banks are watching&#8230; it&#8217;s going to be a battle for distribution." 
On regulation, Perkins applauded recent efforts by the CFTC and the SEC's crypto task force to engage meaningfully with DeFi experts. 
"The very act of understanding informs policy. Hopefully we get to a place where we clarify what is decentralized, what is not, and how it&#8217;s regulated."
Perkins says founder quality is his north star. 
"We invest in the strongest of founders across every single vertical," stressing that CoinFund's thesis rests on one principle: find the value, not just the hype.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45953644/truth-social-etf-filing-bitcoin-ethereum">Truth Social&#8217;s Bitcoin And Ethereum ETF Filing With SEC Aims For 75% BTC, 25% ETH</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Exclusives

Coinfund President On AI Tokens, DePIN, And Why Clear Rules Will Unleash Next Wave Of Crypto Adoption

ILMN

Illumina shares are trading higher after the company announced it was selected by Incyte and QIAGEN to advance precision diagnostics for CALR-driven myeloproliferative neoplasms.

Legal

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Viatris Inc. of Class Action Lawsuit and Upcoming Deadlines - VTRS

Viatris Inc. (VTRS) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris

VTRS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Viatris Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

DEADLINE ALERT for VTRS and CGC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

VTRS Investors Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit with the Schall Law Firm

Viatris Deadline Today: Rosen Law Firm Urges Viatris Inc. (NASDAQ: VTRS) Stockholders With Large Losses to Contact the Firm for Information About Their Rights

June 3, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against VTRS

Kuehn Law Encourages Investors of Viatris Inc. to Contact Law Firm

Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

BGM Group

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Zoetis

Goldman Sachs

Jefferies

Piper Sandler

Barclays

B of A Securities

Screenshot 2024-09-30 at 5.38.54 PM

Movers & Shakers

COSM

Nestle Sponsored representing Registered Shares Series B

NSRGY

How Cosmos Health&#39;s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

지난주에 가장 저조한 성과를 보인 12개의 대형주는 다음과 같다.
<ol>
<li>슈퍼마이크로컴퓨터 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>): 회사의 분기 보고서가 미국 <a href="https://www.benzinga.com//node/44046734" target="_blank" rel="noreferrer noopener">증권거래위원회</a>에 제출된 후 지속적인 변동성으로 인해 26.06% 하락했다.</li>
<li>앱러빈 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>): <a href="https://www.benzinga.com//node/43981217" target="_blank" rel="noreferrer noopener">주식에 대한 여러 개의 공매도 보고서</a>가 발표된 후 21.57% 하락했다.</li>
<li>메이플베어 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>): 4분기 매출이 예상보다 저조하게 나타나고 애널리스트들이 <a href="https://www.benzinga.com//node/43985818" target="_blank" rel="noreferrer noopener">주가 전망을 수정</a>한 후 21.53% 하락했다.</li>
<li>넷앱 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NASDAQ">NTAP</a>): 회사가 예상보다 저조한 3분기 매출 결과를 발표하고 4분기 및 2025회계연도 <a href="https://www.benzinga.com//node/44024261" target="_blank" rel="noreferrer noopener">조정 EPS 가이던스를 발표한</a> 후 19.81% 급락했다.</li>
<li>퓨어 스토리지 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>): 회사가 2026회계연도 <a href="https://www.benzinga.com//node/43989517" target="_blank" rel="noreferrer noopener">매출 가이던스를 예상보다 저조하게 발표</a>한 후 19.36% 하락했다. 애널리스트들은 <a href="https://www.benzinga.com/quote/pstg/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 수정했다</a>.</li>
<li>듀오링고 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>): 엇갈린 4분기 결과를 발표한 후 19.02% 하락다. <a href="https://www.benzinga.com//node/44047945" target="_blank" rel="noreferrer noopener">애널리스트들이 주가 전망을 수정했다.</a></li>
<li>비아트리스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>): 회사가 4분기 EPS와 매출이 예상보다 저조하게 나타나고 2026회계연도 매출 및 <a href="https://www.benzinga.com//node/44019622" target="_blank" rel="noreferrer noopener">및 EPS 가이던스도 예상보다 저조하게 발표한</a> 후 17.96% 하락했다. 뱅크오브아메리카증권 애널리스트 제이슨 게버리(Jason Gerberry)는 시장수익률 하회 의견을 유지하고 <a href="https://www.benzinga.com/quote/vtrs/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 11달러에 10달러로 하향 조정했다.</a></li>
<li>셈프라 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRE#NYSE">SRE</a>): 회사가 4분기 결과를 발표하고 전망을 하향 조정한 후 17.83% 하락했다. 여러 애널리스트들이 <a href="https://www.benzinga.com//node/43984834" target="_blank" rel="noreferrer noopener">목표주가를 수정했다</a>.</li>
<li>팔란티어 테크놀로지 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>): 지난주 보도에서 트럼프 행정부가 <a href="https://www.benzinga.com//node/44032909" target="_blank" rel="noreferrer noopener">국방부에 예산 삭감을 계획하라고 지시했다</a>고 제시한 후 지속적인 약세가 우려되어 16.21% 하락했다.</li>
<li>트립닷컴 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>): 4분기 재무 결과를 발표한 후 15.43% 하락했다.</li>
<li>스트레티지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>): 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://www.benzinga.com//node/44037042" target="_blank" rel="noreferrer noopener">가격 하락</a> 이후 14.77% 급락했다.</li>
<li>테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>): 회사가 1월에 유럽엽합에서 새로운 자동차 등록이 감소한 <a href="https://www.benzinga.com//node/43934934" target="_blank" rel="noreferrer noopener">보고서를 발표한</a> 후 13.27% 하락했다. 이는 매그니피센트 7 종목 중 <a href="https://www.benzinga.com//node/44043021" target="_blank" rel="noreferrer noopener">거의 유일한 급락세를 보인 주식</a>이다.</li>
</ol>
사진 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

비아트리스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>)의 주식이 금요일 오후 4% 이상 하락했지만 최근의 지지선 위에서 거래되고 있었다. 이는 어제 주가가 15% 하락한 후 발생한 일이다. 주가가 하락한 이유는 <a href="https://www.benzinga.com/general/health-care/25/02/44019622/viatris-stock-tumbles-on-q4-earnings-miss-fda-warning-clouds-2025-outlook" target="_blank" rel="noopener" data-google-interstitial="false">이 회사의 실적</a>이 시장 예상보다 저조하게 나타났기 때문이다.
비아트리스의 차트는 중요한 시장 역학을 잘 보여준다. 특정 가격 수준이 다른 가격 수준보다 더 중요하다는 것이다. 그래서 우리 기술 분석 팀은 이것을 <a href="https://kr.benzinga.com/?s=%EC%98%A4%EB%8A%98%EC%9D%98+%EC%A3%BC%EC%8B%9D+" target="_blank" rel="noopener">오늘의 주식</a>으로 선정했다.
일부 주식 시장 분석가들은 랜덤 워크 가설(Random Walk Theory)을 지지한다. 그들은 주가 변동이 무작위적이라고 믿으며, 과거 가격으로 미래 가격이나 추세를 결정할 수 없다고 주장한다.
하지만 이러한 분석은 잘못되었다. 가격 변동이 무작위적이라면 지지선과 저항선은 존재하지 않을 것이다. 모든 가격 수준은 동일하게 중요하지 않게 될 것이다.
하지만 명백히 지지선과 저항선은 존재한다. 거의 모든 차트를 보면 이를 확인할 수 있다.
참고: <a href="https://www.benzinga.com/news/global/25/02/44053592/white-house-meeting-turns-tense-as-trump-warns-zelenskyy-youre-gambling-with-world-war-iii">백악관 회의가 긴장감 돌입, 트럼프가 젤렌스키에게 경고: &#8216;당신은 제3차 세계대전과 도박 중이다.&#8217;</a>
비아트리스의 경우도 마찬가지이다. $13.50 수준은 저항선으로, $8.75 수준은 지지선으로 작용해왔다. 이 두 수준에서의 가격 움직임은 매우 정확했다.
작년 2월 주가가 이 저항선을 시험했을 때, 높은 거래 가격은 $13.48에서 발생했다. 이후 매도세가 발생했지만 주가는 반등하여 2023년 11월에 다시 저항선에 도달했다. 이번에는 높은 거래 가격이 $13.55에서 발생했다.
지지선 주변의 움직임도 매우 정확했다.
주가가 지지선을 찾았을 때, 낮은 거래 가격은 $8.74에서 발생했다. 어제 매도세는 가격이 이 지지선에 가까워지자 멈췄고 주가는 반등했다. 낮은 거래 가격은 $8.77에서 발생했다.
이 수준 주변에 지지가 형성된 이유는 &#8216;판매자 후회(Seller&#8217;s Remorse)&#8217; 때문이다.
2023년 11월에 매도한 사람 중 일부는 주가가 곧바로 반등하자 매도한 것을 실수로 생각했다. 그들은 가능하다면 매도 가격에 다시 주식을 구매하고 싶어 했다.
결과적으로 어제 비아트리스가 이 가격 수준에 가까워지자 매수 주문이 들어왔다. 이러한 주문의 대량 집중이 지지선을 형성하여 가격의 바닥을 만들었다.
숙련된 트레이더들은 시장이 무작위적이지 않다는 것을 알고 있다. 또한 특정 수준이 다른 수준보다 더 중요하다는 것을 알고 있다. 아래에서 볼 수 있는 비아트리스의 차트는 이러한 시장 역학을 명확히 보여준다.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-804349" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28141523/1-4-1024x547.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28141523/1-4-1024x547.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28141523/1-4-300x160.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28141523/1-4-768x411.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28141523/1-4.png 1521w" alt="" width="1024" height="547" /></figure>
주가 움직임: 비아트리스의 주식은 금요일 미국 동부 시간 오후 3시 38분에 4.10% 하락한 $9.14에 거래되었다.
다음 읽어보기:
<ul>
<li><a href="https://www.benzinga.com/news/econ-s/25/02/44041803/federal-reserves-preferred-inflation-gauge-marks-first-slowdown-in-4-months">연준이 선호하는 물가 지표, 4개월 만에 첫 둔화 기록</a></li>
</ul>
이미지 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

JP모건에 따르면 미국 대형 바이오제약주는 2년 연속 전체 시장 대비 저조한 실적을 기록했으며, 2025년에 대한 투자자들의 전망은 혼조세를 보이고 있다.
강력한 펀더멘털과 신약 파이프라인의 발전에도 불구하고 정치적 불확실성과 섹터 순환과 같은 요인으로 인해 S&amp;P 500 대비 바이오제약 섹터의 성과가 저조했다.
2024년 바이오제약 주식은 9.6% 상승하여 S&amp;P 500의 28.5% 상승률에 미치지 못했다. 그러나 JP모건 애널리스트들은 몇몇 주요 기업에 대해 긍정적인 전망을 유지하고 있다.
JP모건에서 가장 많이 추천하는 일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)는 당뇨병 및 비만 치료제인 <a href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua">마운자로(Mounjaro)와 젭바운드(Zepbound)</a>에서 지속적인 성장을 보일 것으로 예상된다. 또한 JP모건은 일라이 릴리의 강력한 파이프라인을 강조하면서 2030년대까지 두 자릿수 매출과 수익 성장을 예측했다.
브리스톨-마이어스 스퀴브(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)는 최고 매출 100억 달러를 달성할 수 있는 조현병 치료제인 코벤피(Cobenfy)의 강력한 잠재력으로 JP모건의 &#8216;포커스 리스트&#8217;에 추가되었다.
마찬가지로 머크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)와 리제네론 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40168774/mercks-blockbuster-vaccine-gardasil-sales-in-china-analyst-highlights-challenges-an">주요 제품에 영향을 미치는</a> <a href="https://www.benzinga.com/general/biotech/24/04/38208816/eye-drug-eylea-price-manipulation-regeneron-faces-us-justice-department-allegations-over-medicare">경쟁 압력</a> 및 지역 역학과 관련된 2024년의 어려움에 이어 2025년에는 회복될 것이르오 예상된다.
길리어드 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)는 <a href="https://www.benzinga.com/quote/GILD">HIV 예방을 위한</a> 레나카파비르(lenacapavir)의 2025년 중반 출시가 예상됨에 따라 성장할 것으로 예상된다.
또한 애브비(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)는 단기적인 <a href="https://www.benzinga.com/quote/ABBV">파이프라인 개발</a>이 적음에도 불구하고 스카이리지(Skyrizi)와 린보크(Rinvoq) 판매 호조에 힘입어 밸류에이션이 매력적이라고 보았다.
한편, 동물 건강 관련 주식도 2025년에 반등할 것으로 예상한다. JP 모건은 조에티스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>)를 이 분야에서 가장 강력한 선택지로 보고 있으며, 고배당 매출 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41722660/zoetis-q3-earnings-beat-companion-animal-segment-growth-gives-confidence-into-2025-" target="_blank" rel="noreferrer noopener">성장과 마진 확장</a>의 잠재력을 언급했다. 아이덱스 래버러토리스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>)는 또 다른 다른 확실한 선택이며, 성과는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41659873/idexx-laboratories-adjusts-guidance-as-q3-revenue-growth-slows-analyst-notes-fewer-" target="_blank" rel="noreferrer noopener">수의사 방문 수 회복</a>에 달려 있다. 한편 엘랑코 애니멀 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>)는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41817807/elanco-animal-q3-earnings-profit-beat-new-products-and-stabilized-business-to-drive" target="_blank" rel="noreferrer noopener">신제품 출시</a>와 관련된 불확실성에 직면해 있다.
그리고 특수 의약품 부문은 2024년에 가격 안정성과 공급 역학 개선의 혜택을 받아 조기에 안정화 조짐을 보였다. 페리고(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>)와 비아트리스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>)는 유망한 기회로 강조되었으며 테바 파마슈티컬(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>)는 올해 강력한 임상 시험 <a href="https://www.benzinga.com/general/biotech/24/12/42561832/teva-pharmaceutical-releases-impressive-phase-2-candidate-data-for-gastro-related-diseases" target="_blank" rel="noreferrer noopener">결과를 발표했지만</a> 성장 문제에 직면할 수 있다.
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%ED%80%80%ED%85%80-%EC%BB%B4%ED%93%A8%ED%8C%85-%EB%B8%94%EB%9E%99%EB%B2%A0%EB%A6%AC-%EB%A3%A8%EC%8B%9C%EB%93%9C-%EB%93%B1-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EB%8C%80-%EC%83%81%EC%8A%B9%ED%95%9C/">퀀텀 컴퓨팅, 블랙베리, 루시드 등 지난주 최대 상승한 중형주 (12월 16일~20일)</a>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

미국 주식 시장은 목요일(7일) 연준이 예상대로 금리 인하를 결정하고, 제롬 파월 연준 의장이 <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41823887/powell-dismisses-talk-of-resignation-after-trump-victory-says-policy-is-still-res" target="_blank" rel="noopener"> 도널드 트럼프 당선</a> 이후 사임 또는 해임 가능성을 일축하며 시장을 안심시킨 기자회견 이후 사상 최고치로 마감했다.
SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE" target="_blank" rel="noopener">SPY</a>)로 추적되는 S&amp;P 500 지수는 0.7% 상승한 5,973포인트로 마감했다.
기술주가 시장수익률을 초과 달성했으며, Invesco QQQ Trust(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)로 추적되는 나스닥 100 지수는 1.5% 상승한 21,000포인트 사상 최고치를 기록했다.
특히, 마이크로소프트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE" target="_blank" rel="noopener">MSFT</a>), 애플(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ" target="_blank" rel="noopener">AAPL</a>), 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ" target="_blank" rel="noopener">NVDA</a>), 알파벳(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ" target="_blank" rel="noopener">GOOG</a>, <a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ" target="_blank" rel="noopener">GOOGL</a>), 아마존(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ" target="_blank" rel="noopener">AMZN</a>), 메타 플랫폼스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ" target="_blank" rel="noopener">META</a>), 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ" target="_blank" rel="noopener">TSLA</a>)로 구성된 &#8216;매그니피센트 세븐&#8217;의 총 시가총액이 17조 달러를 초과하여 새로운 정점을 기록했다.
다우존스 지수는 수요일에 3.6% 상승한 후 주춤했으며, 소형주 지수는 전날 5.8% 급등 후 0.4% 하락했다.
S&amp;P 500 지수에서 가장 성과가 좋았던 섹터는 기술 섹터로 1.8% 상승했으며, 통신서비스와 소비재 섹터가 각각 1.3% 상승했다. 수요일에 가장 많이 상승했던 금융주는 목요일에 1.5% 하락하면서 부진한 모습을 보였다.
<h3 class="wp-block-heading">연준, 금리인하 그리고 파월 거취 우려 일축</h3>
연방준비제도이사회는 예상대로 금리를 4.5%~4.75%로 0.25% 인하했는데, 이는 9월의 0.5% 대규모 인하 이후 완화 속도가 줄어든 것이다. 연준은 2분기 미국 국내총생산(GDP)이 2.8% 상승하고 소비자 신뢰가 회복되는 등 견고한 경제 모멘텀을 인정했다.
파월 의장은 10월 고용지표의 부진을 일축했으며, 일자리 성장 정체는 근본적인 경제 약세보다는 파업과 허리케인 같은 일시적인 요인에 기인한 것이라고 지적했다.
파월 의장은 이번 금리 인하를 통화 정책의 "추가 재조정(further recalibration)&#8221;의 일환으로 설명하며, 여전히 "제약적(restrictive)&#8221;이라고 했다. 그는 향후 추가 완화 가능성을 암시했지만 12월 회의에서 구체적인 금리 인하 시그널을 보내지 않고 데이터에 의존하는 접근 방식을 강조했다.
트럼프 대통령의 요청이 있으면 사임할 것이냐는 질문에 파월은 "아니오"라고 단호하게 답하며 대통령에게는 연준 의장을 해임할 법적 권한이 없다는 점도 거듭 강조했다.
파월 의장의 발언 이후 12월 금리 인하에 대한 시장 기대치는 75%까지 치솟으며 수요일 선거 이후 하락세를 회복했다. 국채수익률은 급격히 하락하여 10년물 수익률은 10bp 하락한 4.33%로 전날의 급등분을 거의 상쇄했다.
미국 달러는 0.7% 하락했으며, SPDR Gold Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE" target="_blank" rel="noopener">GLD</a>)로 추적되는 금 가격은 수요일 3% 하락한 후 목요일에는 1.8% 반등했다.
한편, 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)은 뉴욕시간 오후 4시 30분에 1% 상승 거래되었으며, 세션 중에 76,990달러로 사상 최고가를 기록했다.
<h3 class="wp-block-heading">목요일 S&amp;P 500 상위 5개 상승주</h3>
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>이름</td>
<td>종가</td>
<td>변동 %</td>
</tr>
<tr>
<td>EPAM 시스템즈 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAM#NYSE">EPAM</a>)</td>
<td>233.00</td>
<td>14.95%</td>
</tr>
<tr>
<td>비아트리스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>)</td>
<td>13.20</td>
<td>13.69%</td>
</tr>
<tr>
<td>슈퍼 마이크로 컴퓨터 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)</td>
<td>25.47</td>
<td>12.21%</td>
</tr>
<tr>
<td>워너 브라더스 디스커버리 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>)</td>
<td>9.38</td>
<td>11.91%</td>
</tr>
<tr>
<td>맥케슨 코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>)</td>
<td>607.76</td>
<td>10.64%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">목요일 S&amp;P 500 상위 5개 하락주</h3>
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th>이름</th>
<th>종가</th>
<th>변동 %</th>
</tr>
</thead>
<tbody>
<tr>
<td>매치 그룹 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>)</td>
<td>31.11</td>
<td>-17.86%</td>
</tr>
<tr>
<td>APA 코퍼레이션 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>)</td>
<td>21.93</td>
<td>-11.34%</td>
</tr>
<tr>
<td>CVS 헬스 코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</td>
<td>57.09</td>
<td>-7.33%</td>
</tr>
<tr>
<td>로크웰 오토메이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>)</td>
<td>277.22</td>
<td>-5.71%</td>
</tr>
<tr>
<td>벡톤 디킨슨 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>)</td>
<td>227.16</td>
<td>-5.38%</td>
</tr>
</tbody>
</table>
</figure>
더 읽기: <a href="https://kr.benzinga.com/news/usa/economy/%EC%97%B0%EC%A4%80%EC%9D%98-%EA%B8%88%EB%A6%AC-%EC%9D%B8%ED%95%98-%EC%86%8D%EB%8F%84%EA%B0%80-%EB%91%94%ED%99%94%EB%90%A0-%EA%B2%83%EC%9C%BC%EB%A1%9C-%EC%98%88%EC%83%81-%EA%B2%BD%EC%A0%9C%ED%95%99/">연준의 금리 인하 속도가 둔화될 것으로 예상: 경제학자들, 트럼프의 백악관 복귀에 주목</a>
이미지: MidJourney 통해 인공지능으로 생성됨
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Bonds

Broad U.S. Equity ETFs

Treasuries

Econ #s

Federal Reserve

ETFs

AAPL

AMZN

EPAM

GOOG

GOOGL

MSFT

MTCH

NVDA

파월 연설 후 미국 증시 사상 최고치, '매그니피센트 세븐' 총 시가총액 17조 달러 돌파

주식 시장 지수는 최근 몇 년간 사상 최고치를 기록했으며 S&amp;P 500은 조 바이든 대통령이 지난 <a href="https://www.benzinga.com/general/education/24/02/37275812/if-you-invested-in-the-s-p-500-when-joe-biden-became-president-heres-how-much-youd-have-today" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">거의 4년 동안</a> 국가를 이끌었던 다른 해를 능가했다.
바이든이 취임하면서 모든 주식이 상승한 것은 아니며 투자자들은 2024년 선거가 다가올 때 앞으로 있을 일에 대비하기 위해 2021년 최악의 성과를 낸 주식을 되돌아보고 싶을 수도 있다.
무슨 일이 (What Happened): 바이든이 올해 초 <a href="https://www.benzinga.com/topic/2024-election" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">2024년 대통령 선거</a>에서 하차한다고 발표했다. 현 대통령이 재선되지 못하더라도, 민주당 대통령 하의 과거 성과는 카멀라 해리스가 다가오는 화요일 선거에서 승리할 경우 어떤 주식과 섹터가 승자가 될 수 있는지를 강조할 수 있다.
SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)가 추적하는 S&amp;P 500은 2021년에 26.9% 상승했다. 이는 2018년 이후 연간 최고 실적이자 지난 11년 동안 주요 주식 시장 지수 중 두 번째로 좋은 실적을 기록했다.
2020년 11월 3일, 바이든이 승리한 대선 이후 12개월 동안 <a href="https://www.benzinga.com/news/22/01/25137004/biden-vs-trump-how-did-stock-market-returns-compare-after-their-first-year-as-president" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">S&amp;P 500 지수는 37.4% 상승</a>했다. 이는 수년 동안 한 대통령 하의 최고의 1년 시장 수익률이었다.
많은 주식들이 2021년에 상승했지만, 모든 상장 회사들이 긍정적인 수익률을 기록한 것은 아니다.
StatMuse의 <a href="https://www.statmuse.com/money/ask/worst-performing-stocks-in-2021-in-the-s-and-p-500" target="_blank" rel="noreferrer noopener">보고서</a>에 따르면 2021년에 가장 실적이 저조했던 S&amp;P 500 주식 10개와 해당 섹터는 다음과 같다:
Here were the 10 best-performing S&amp;P 500 stocks in 2021, according to a <a href="https://www.statmuse.com/money/ask/worst-performing-stocks-in-2021-in-the-s-and-p-500" target="_blank" rel="noreferrer noopener">report </a>from StatMuse, and their sectors.
아래는 2021년 S&amp;P 500 지수에서 가장 성과가 저조했던 10개 주식과 그 섹터들입니다:
1. 라스베이거스 샌즈 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>): -37.1%, 소비재/카지노 
2. 글로벌 페이먼츠 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>): -36.8%, 금융 
3. 마켓 액세스 (NASDAQ::MKTX): -28.1%, 금융 
4. 비아트리스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>): -25.8%, 헬스케어 
5. 윈 리조트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>): -24.8%, 소비재/카지노 
6. 워너 브라더스 디스커버리 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>): -24.4%, 미디어/오락 
7. 팔란티어 테크놀로지스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>): -23.8%, 기술 
8. 피델리티 내셔널 인포메이션 서비스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>): 금융 
9. 페이팔 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>): -20.7%, 금융 
10. 이리 인뎀니티 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIE#NASDAQ">ERIE</a>): -20.3%, 보험
위의 결과는 2021년에 금융 섹터가 저조한 성과를 보였으며, 카지노 주식들이 여러 개 포함되어 있음을 보여준다.
The results above show that financials was an underperforming sector in 2021 and also includes several casino stocks on the list. Peak at the top<a href="https://www.benzinga.com/news/21/12/24848823/10-worst-performing-s-p-500-stocks-of-2021" target="_blank" rel="noopener" data-google-interstitial="false"> 10 best performing</a> S&amp;P 500 stocks here.
알고 계셨나요?
&#8211; 국회가 큰 투자를 하고 있습니다. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent110224" target="_blank" rel="noreferrer noopener">2024년 대선 전 그들이 무엇을 사고 팔았는지에 대한 팁을 우리 도구로 쉽게 확인하세요.</a>
왜 중요한가 (Why It's Important): 클릭하면 도널드 트럼프의 백악관 입성 첫해인 2017년 S&amp;P 500의 <a href="https://www.benzinga.com/general/politics/24/10/41584466/these-10-stocks-were-the-best-s-and-p-500-performers-in-2017-when-trump-was-president-will-history-r" target="_blank" rel="noreferrer noopener">10개 최고 주식</a> 및 최악의 성과 <a href="https://www.benzinga.com/general/politics/24/10/41606114/10-s-and-p-500-stocks-were-worst-performers-in-first-year-of-trumps-presidency-will-they-sink-again" target="_blank" rel="noreferrer noopener">10개 최악의 주식</a>을 확인할 수 있다.
투자자들에게 흥미로운 점은 백악관에 누가 있었는지에 따라 일부 주식의 상관관계가 있을 수 있다는 점이다.
윈 리조트는 2017년 트럼프 하에 S&amp;P 500 지수에서 4위로 좋은 성과를 보였지만, 2021년 바이든 하에서는 저조한 성과를 보였다. 페이팔은 2017년 S&amp;P 500 지수에서 8위로 좋은 성과를 보였지만, 2021년에는 저조한 성과를 보였다.
위의 결과는 과거 결과와 민주당 리더십을 바탕으로 해리스가 대통령에 당선될 경우 금융주와 카지노 주식이 저조한 성과를 낼 수 있음을 보여줄 수 있다.
2024년 대선이 며칠도 채 남지 않은 시점에서, 투자자들은 트럼프나 해리스의 승리를 기준으로 포트폴리오를 조정하고 있을 가능성이 높다. 접전이 예상되는 대선에서 투자자들은 두 후보 하에서 혜택을 받을 수 있는 섹터를 살펴보는 것이 좋다.
프리덤 캐피털 마켓(Freedom Capital Markets)의 수석 글로벌 전략가 제이 우즈(Jay Woods)는 이전에 트럼프 또는 해리스가 2024년 선거에서 승리하는지 여부에 관계없이 이익을 얻을 수 있는 <a href="https://www.benzinga.com/etfs/sector-etfs/24/08/40515453/exclusive-trump-or-harris-12-stocks-2-etfs-could-win-no-matter-whos-president-says-market-strate" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">일부 섹터 및 주식</a>을 벤징가와 공유했다.
우즈는 방산 주식과 사이버 보안 주식을 2024년 대선 전에 주목해야 할 주요 섹터로 언급했다.
우즈는 방산 부문에 대해 &#8220;이 부문을 면밀히 관찰해야 한다고 생각한다&#8221;고 말했다.
그는 방산 주식이 지정학적 우려와 세계의 많은 불리한 사건들로 인해 계속 혜택을 받을 수 있다고 덧붙였다.

다음 읽기:
&#8211; <a href="https://www.benzinga.com/general/sports-betting/24/10/41589659/trump-vs-harris-state-by-state-2024-election-betting-odds-which-candidate-is-favored-to-wi" target="_blank" rel="noreferrer noopener">트럼프 대 해리스: 주별 2024년 대선 배당률, 각 후보가 당신의 지역사회에서 승리할 가능성은?</a>
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Market Summary

ERIE

MKTX

PYPL

WYNN

바이든 대통령 첫 해에 S&P 500 최악의 실적 10종목: 2024년 해리스 당선시 추세가 지속?

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>워너 브라더스 디스커버리(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>)의 주가는 회사가 <a href="https://www.benzinga.com//node/39838603" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">기존 텔레비전 네트워크</a>에서 디지털 스트리밍 및 스튜디오 사업을 분할하려는 계획을 논의했다는 보고 이후 18.28% 상승했다.</li>
<li>마이크로스트레티지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>)의 주식은 지난주 비트코인 가격의 상승 속에서 16.74% 상승했다.</li>
<li>D.R. 호튼(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>)의 주가는 회사가 예상보다 나은 3분기 재무 결과를 보고하고 FY24 지침을 수정한 후 12.91% 급등했다. 회사는 또한 <a href="https://www.benzinga.com//node/39845136" target="_blank" rel="noreferrer noopener">새로운 40억 달러 규모의</a> 자사 주식 매입을 승인했다. 주식에 대한 목표 주가를 <a href="https://www.benzinga.com/quote/dhi/analyst-ratings" target="_blank" rel="noreferrer noopener">상향 조정</a>을 한 분석가는 거의 없다.</li>
<li>코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)의 주식은 지난주 비트코인 가격 상승의 영향으로 12.39% 상승했다.</li>
<li>블루 아울 캐피털(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OQL#NYSE">OQL</a>)은 블룸버그가 아탈라야(Atalaya)를 약 8억 달러에 매수할 계획이라고 <a href="https://www.bloomberg.com/news/articles/2024-07-16/blue-owl-to-buy-private-credit-firm-atalaya-adding-10-billion-in-assets?sref=2h1zKciy" target="_blank" rel="noreferrer noopener">발표</a>한 후 7.89% 상승했다.</li>
<li>유나이티드헬스 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)의 주가는 <a href="https://www.benzinga.com//node/39790051" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">2분기 실적 호조</a>에 따라 7.84% 상승했다. 많은 분석가들이 주식에 대한 가격 예측을 <a href="https://www.benzinga.com//node/39814804" target="_blank" rel="noreferrer noopener">상향 조정했</a>다.</li>
<li>스테이트 스트리트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STT#NYSE">STT</a>)는 예상보다 나은 <a href="https://www.benzinga.com//node/39795949" target="_blank" rel="noreferrer noopener">2분기</a> 실적에 힘입어 7.21% 급등했다. 몇몇 분석가들은 주식 가격 예측을 <a href="https://www.benzinga.com//node/39822388" target="_blank" rel="noreferrer noopener">수정</a>했다. </li>
<li>레나(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>)는 다른 주택 건설업체 주식들과의 공감을 이유로 7.07% 상승했다.</li>
<li>토스트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>)는 미즈호(Mizuho)가 주식을 중립에서 아웃퍼폼(Outperform)으로 <a href="https://www.benzinga.com/quote/TOST/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">상향 조정하고</a> 목표 주가를 21달러에서 33달러로 상향 조정한 후 지난주 주가는 7.05% 상승했다. </li>
<li>이팸 시스템(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAM#NYSE">EPAM</a>)의 주식은 제프리스(Jefferies)의 분석가가 <a href="https://www.benzinga.com/quote/epam/analyst-ratings" target="_blank" rel="noreferrer noopener">보유에서 매수로</a> 등급을 올린 후 6.97% 상승했다.</li>
</ol>
사진=Shutterstock의 rafapress






Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Viatris

뉴스

에 대한 최신 뉴스 Viatris (NASDAQ:VTRS) 주식

일요일, 3월 02, 2025

금요일, 2월 28, 2025

월요일, 12월 23, 2024

목요일, 11월 07, 2024

토요일, 11월 02, 2024

월요일, 7월 22, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌